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Abstract
It is difficult at present to predict the long-term course of steroid sensitive nephrotic syndrome
(SSNS) regarding the probability of relapse. We retrospectively reviewed 42 SSNS patients who
had been followed up for a mean duration of 10 ±3 years. Male was predominantly affected (M:F =
3.5:1). Sixty percent of our children presented between 2 to 5 years old. At the time of last follow-
up, seven patients (17%) never had a relapse. Twenty-three patients (55%) went into long-term
remission and 12 (28%) continued to have active disease. Kidney biopsies were performed in 18
patients (43%). The most common histology was minimal change disease (71%), followed by IgM
nephropathy (28%). Thirty-four patients (81%) followed the steroid treatment protocol of the
International Study of Kidney Disease in Childhood (ISKDC). Sixteen patients (38%) required second
line medications. The most common steroid sparing agents used were levamisole, followed by
cyclophosphamide and cyclosporin A. The nonrelapsers had a higher serum albumin than the
relapsers, with a p value of 0.03. From the second year of follow-up onwards, the long-term remission
group had fewer episodes of relapses than the active disease group, with a p value of ≤ 0.034 at
the second subsequent years. The median time to achieve the long-term remission is 3 years (95%
confidence interval: 1.85-4.15) in our patients. Among all the prognostic factors studied, a higher
serum albumin at presentation and a fewer number of relapses per year appeared to be related to
a less relapsing course.
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INTRODUCTION
Nephrotic syndrome is characterized by heavy
proteinuria, hypoalbuminemia and edema. In children,
majority of patients with idiopathic nephrotic syndrome
respond to steroid therapy and is associated with minimal
histological changes in the glomeruli (1,2). Their
excellent response to steroid therapy and high frequency
of relapses are well known to pediatricians (3). Although
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numerous studies have been carried out to identify the
prognostic factors, it is still difficult to predict the long-
term clinical course regarding relapses of this group of
patients, particularly at the time of initial presentation.
We retrospectively reviewed our patients with idiopathic
nephrotic syndrome. Apart from describing their clinical
courses and outcomes, we also look for any factors that
could predict their outcomes.
PATIENTS AND METHODS
Patients
Between January 1980 and December 1993, 113 patients
with the diagnosis of nephrotic syndrome were identified
in the unit records, which only registered the diagnosis
and biographic data of the patients. Full medical records
were only available for analysis in 46 patients. Four
patients were not included in the study. One patient in
fact suffered from congenital nephrotic syndrome.
Another one patient suffered from IgA nephropathy and
two had focal segmental glomerulosclerosis. All the
remaining 42 patients fulfilled the following criteria:
They presented in the period from January 1980 to
December 1993;  they had been fol lowed up
consecutively for at least 5 years; they were steroid
responsive and no secondary cause was identified for
the nephrotic syndrome.
Definitions
Response was defined as a reduction in rate of urinary
excretion of protein to less than 4 mg/hour/m2 body
surface area (BSA) for 3 consecutive days.
Relapses were defined as the reappearance of proteinuria
greater than or equal to 40 mg/hour/m2 BSA (Albustix
++ or more) for 3 consecutive days.
International Study of Kidney Disease in Childhood
(ISKDC) steroid regime was defined as daily prednisone
dosage (60 mg/m2/day in divided doses) for 4 weeks and
followed by intermittent dosage (40 mg/m2/day on
alternate day) for 4 weeks (4).
Steroid responsive was defined as remission of nephrotic
syndrome during the initial 8 weeks of steroid treatment.
Time to achieve first remission was defined as the time
from starting steroid therapy to the first day on which a
response was observed (5).
Time to first relapse was defined as the time interval from
the first presentation to the first relapse (5).
Long-term remission was defined as no relapse of
nephrotic syndrome for at least 3 consecutive years (6).
Active disease was defined as having a relapse within a
3-year period (6).
Nonrelapser was defined as a patient who never has a
relapse during the period of follow-up.
Frequent relapser was defined as a patient who has four
or more relapses within any 12-month period.
Method of study
The patients were categorized nonrelapsers or relapsers
at their last follow-up. The relapsers were subdivided
into active disease group or long-term remission group;
according to their clinical status at the last follow-up.
From the patients' records, the following parameters were
retrieved:
1. age when the child was first presented;
2. laboratory parameters noted on the first presentation
and these included white cell count, hemoglobin,
serum urea, serum creatinine, albumin/globulin ratio,
serum cholesterol, 24-hour proteinuria and creatinine
clearance;
3. the time to achieve first remission; and
4. the time to first relapse and the number of relapses
reported in the follow-up of each year.
In order to examine whether frequent relapsers,
infrequent relapsers and patients who relapsed within or
after the first 6 months of the disease, behaved differently,
we also categorized the patients according to the disease
in their first year and compared their differences in
outcome subsequently.
Statistical analysis
Parametric data was analyzed by the unpaired Student's
t test. The Fisher's exact test was used to compare the
outcome of different groups of patients. A p value less
than 0.05 was considered to be statistically significant.
The time to achieve long-term remission was reckoned
by the Kaplan-Meier survival analysis.
RESULTS
Forty-two patients were identified. Of them, 41 were
Chinese and one was Indian. Male to female ratio was
3.5 to 1. Twenty-five (60%) patients presented between
2 and 5 years old. The peak age at presentation was
between 2 and 3 years old (Fig. 1). The mean duration
of follow-up was 10 ±3 years, ranging from 5 to 15 years.
During the follow-up period, seven patients (17%) never
had a relapse and 35 (83%) had at least one relapse. At
the time of the last follow-up, of the 35 patients, 33 (66%)
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achieved long-term remission and 12 (34%) continued
to have active disease (Fig. 2). Twelve patients had not
been assessed for more than 1 year. All of them were in
the long-term remission group. Their disease had been
inactive for years (mean = 8 years) and many of them
were near their adulthood. They were advised to come
to our clinic when there was a breakthrough relapse. The
changes in number of patients were shown in figure 3.
Twenty-five patients had been followed up for 10 years
and six of them (24%) still have active disease. Seven
patients had been followed up for 15 years and one of
them (15%) was still relapsing. By using the Kaplan-
Meier method, the median time to achieve long-term
remission in our group of patients was 3 years (95%
confidence interval 1.85-4.15) and the mean time was 6.
26 years (SE: 0.88). The mean time to achieve remission
in these 42 patients was 12.7 ±13.3 days in their first
presentation. The mean time to have first relapses in the
35 relapsers was 5.7 ±9.5 months after their first
presentation. Steroid regime in 34 patients followed the
ISKDC and one patient remitted spontaneously without
medication.
Twenty-one renal biopsies were performed in 18 patients.
The indications were frequent relapses in 14 patients,
late responder in two, history of macrohematuria in one
and partial response to steroid therapy in one. Fifteen
biopsies (71%) showed minimal changes disease and five
showed evidence of mesangial proliferation with
significant mesangial IgM deposition and were classified
as IgM nephropathy. One biopsy showed focal segmental
mesangial hypercellularity with mesangial deposition of
IgA, IgM and C3, which may suggest an early IgA
nephropathy. Three patients had a second kidney biopsy.
Figure 1.  The age at presentation of the 42 SSNS patients. The
peak age at presentation was between 2 to 3 yeas old and 60% of
patients presented between 2 to 5 years old.
Figure 2.  Patients are categorized into relapser, nonrelapser, long-
term remission and active disease groups according to the clinical
status at their last follow-up.
Figure 3.  Number of patients who are actively followed up from
1993 to 1998.
Figure 4.  The group of patients in long-term remission showed fewer
number of relapses per year than the group with active disease. The
difference became statistically significant from the second year of
follow-up onwards. R1 = patients with long term remission in first
year; AD1 = patients with active disease in the first year
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The indication in two patients was an increase in
frequency of relapses after the cessation of cyclosporin
A and histologically they showed morphological
transition from minimal change disease to mesangial
proliferation. The third patient had his first kidney biopsy
because of his partial response to steroid therapy and his
first kidney biopsy showed minimal changes disease. In
his subsequent relapses, he became steroid resistant and
his repeated kidney biopsy did not show any deterioration
or changes as compared with his first biopsy. He achieved
long-term remission after a course of cyclophosphamide.
Thirty-five patients had at least one relapse in their
clinical course. Of them, 28 relapsed within the first 6
months after their first presentation (group A) and six
relapsed after the first 6 months of the disease (group
B). One patient attained partial remission after steroid
therapy. Seventeen patients in group A and five in group
B went into long-term remission at their last follow-up.
Statistical testing did not show any significant association
between the outcome and relapse within or after the first
6 months of the disease (Table 1).
In the first year of follow-up, 26 patients were infrequent
relapsers and eight were frequent relapsers. Nineteen
patients from the infrequent relapser and three from the
frequent relapser group achieved long-term remission.
However, they did not show any statistical significant
difference in outcome between the two groups (Table
2).
In the group of nonrelapsers (n = 7), the mean duration
of follow-up was 11.7 ±2.5 years (ranged 8-15 years).
Five of them adopted the steroid regime suggested by
the ISKDC. Because of their good response to steroid
therapy, renal biopsies were not performed. Statistical
analysis between the relapsers and nonrelapsers showed
no significant difference between them in terms of the
age at presentation, white cell count, hemoglobin, serum
urea, serum creatinine, cholesterol, degree of proteinuria,
creatinine clearance and the time to achieve the first
remission. However, the nonrelapser group had a mean
serum albumin of 19.3 ±2.8 g/L and mean serum albumin/
globulin ratio of 1 ±0.3 while that were 15.8 ±3.8 g/L
(p = 0.03) and 0.7 ±0.2 (p = 0.02) respectively in the
relapser group (Table 3). When we examined the
subgroups in the relapsers, the difference noticed was
due to the difference in serum albumin between the
nonrelapses and the long-term remission group with a
p value of 0.007. The nonrelapsers also showed a shorter
time to remission than the active disease group with
p value of 0.045.
Among the 35 relapsers, 23 went into long-term
remission at their last follow-up while 12 still had active
disease. The number of relapses in each year of follow-
up showed significant difference between the two groups
from the second year of follow-up onwards. In the long-
term remission group, the mean number of relapses was
1.6 ±1.2 in the second year, 0.8 ±0.8 in the third year,
0.4 ±0.8 in the fourth year and 0.2 ±0.4 in the fifth year
of follow-up. In the contrary, the active disease group
had a higher number of relapses per year, i.e. 2.6 ±1.4
relapses in the second year, 2.5 ±1.1 in the third year,
1.5 ±1.4 in the fourth year and 1.9 ±1.5 in the fifth year
(Fig. 3).
From the long-term remission group, 19 patients were
treated according to the ISKDC steroid protocol. Steroid-
sparing agents were only used in six patients (24%). Two
patients were on cyclophosphamide, which was started
1 year after the diagnosis of the disease and both of them
went into long-term remission subsequently. One patient
was put on cyclosporine A and three were put on
Table 1.  Difference in outcome between patients relapsed within the first 6 months (group A) and those relapsed after the first 6 months
from first presentation (group B).
Active disease Long-term remission Total
Group A 11 (32%) 17 (50%) 28 (82%)
Group B 1 (3%) 5 (15%) 6 (18%)
Total 12 (35%) 22 (65%) 34 (100%)
The two-sided p value is 0.39 by using the Fisher's exact test.
Table 2.  Difference in outcome between the frequent relapsers and infrequent relapsers.
Active disease Long-term remission Total
Frequent relapsers 5 (15%) 3 (9%) 8 (24%)
Infrequent relapsers 7 (21%) 19 (56%) 26 (76%)
Total 12 (35%) 22 (65%) 34 (100%)
The two-sided p value is 0.09 by using the Fisher's exact test.
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levamisole. In this group, renal biopsies were performed
in nine patients. Six biopsies showed minimal changes
disease, two were classified as IgM nephropathy and one
suggested the possibility of early IgA nephropathy.
Among the 12 patients with active disease, five were
classified as frequent relapsers and seven infrequent
relapsers. Steroid regime in 10 patients followed the
ISKDC protocol. Ten patients (83%) were on steroid
sparing agents. Levamisole was the most commonly used
steroid sparing drug (eight patients), followed by
cyclophosphamide (six patients) and cyclosporine A (five
patients). Seven patients were on different combinations
of steroid sparing drugs, which were taken at different
time interval during the course of the disease. In this
g roup  o f  pa t i en t s ,  t he  mean  t ime  to  s t a r t
cyclophosphamide was 5 years from the onset of disease.
(The range was from 1 to 10 years). Kidney biopsies
were performed in nine patients. Six biopsies showed
minimal change disease and three showed IgM
nephropathy.
Statistical analysis between the long-term remission and
active disease groups did not show any difference in the
age at presentation, white cell count, hemoglobin, serum
urea, creatinine, cholesterol, albumin/globulin ratio,
degree of proteinuria, creatinine clearance, time to
achieve the first remission and the time to have the first
relapse (Table 4). None of our patient had impaired renal
function and none of them died of the disease itself or its
complications.
DISCUSSION
Nephrotic syndrome represents the physiological
consequences of massive proteinuria, leading to
hypoalbuminemia, edema and hypercholesterolemia.
Majority of children had primary form of nephrosis,
which encompasses the spectrum of minimal change
nephrotic syndrome (MCNS), focal segmental
glomerulosclerosis and histopathological variants of
these lesions (7-9). In the early report of ISKDC, 92%
of steroid responsive nephrotic syndrome had minimal
change disease and 93% of patients with minimal change
disease responded to steroid therapy (10). Steroid
responsiveness enables us to identify patients with
MCNS and is so far the best indicator of outcome.
Table 3.  Comparing the clinical and laboratory parameters between the nonrelapsers and relapsers at initial presentation.
Mean value Nonrelapsers Relapsers p value
Age at presentation (month) 46.3 ±33.3 48.5 ±25.4  0.83
White cell count (x109/L) 11.8 ±1.7  9.8 ±2.3 0.1
Hemoglobin (g/dL) 13.4 ±1.0 13.7 ±1.5 0.57
Urea (mmol/L) 4.5 ±1.5 6.5 ±5.1 0.31
Creatinine (µmol/L) 41.0 ±19.7 45.5 ±16.1 0.58
Serum albumin (g/dL) 19.3 ±2.8 15.8 ±3.8 0.03 *
Serum globulin (g/dL) 19.6 ±3.8 22.1 ±3.8 0.14
Albumin/globulin ratio 1.0 ±0.3 0.7 ±0.2  0.01 *
Cholesterol (mmol/L) 11.7 ±2.6 12.1 ±3.4 0.74
Proteinuria (mg/m2/hour) 116.0 ±107.5 292.3 ±263 0.36
Creatinine clearance (mL/minute/1.73 m2) 68.7 ±21.1 95.3 ±60.6 0.47
Time of remission (day) 7.0 ±3.5 14.1 ±14.2 0.27
*p value is statistically significant.
Table 4.  Comparing the clinical and laboratory parameters between the active disease and long-term remission groups at initial presentation.
Mean value Active disease group Long-term remission group p value
Age at presentation (month) 48.7 ±23.5 48.5 ±26.9 0.98
White cell count (x109/L) 10.9 ±2.4 9.1 ±2.2 0.07
Hemoglobin (g/dL) 13.9 ±1.6 13.7 ±1.4 0.75
Urea (mmol/L) 7.4 ±7.7 6.0 ±3.2 0.49
Creatinine (umol/L) 46.5 ±20.5 44.8 ±13.2 0.78
Albumin/globulin ratio 0.78 ±0.3 0.72 ±0.2 0.51
Cholesterol (mmol/L) 11.0 ±1.9 12.7 ±3.8 0.26
24 hours proteinuria (mg/m2/hour) 253.5 ±181.3 315.6 ±305.4 0.59
Creatinine clearance (mL/minute/1.73 m2) 104.0 ±67.2 88.4 ±57.5 0.60
Time to achieve remission (day) 10.3 ±2.4 16.5 ±17.7 0.26
Time to first relapse (month) 4.0 ±2.2 8.3 ±12.0 0.23
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However, relapses do occur for many years and not
uncommonly, these children continue to have relapses
in their adult lives.
Siegel et al (11) reviewed their 61 children with steroid
sensitive nephrotic syndrome (SSNS). Among the 21
steroid responder, who had been followed up for 15 years,
three continued to relapse. Koskimes et al (12) also
reported their 94 SSNS patients who had been followed
up for 5 to 14 years; 18 (19%) were still relapsing.
Similarly, in our patients, 24 % of those followed up for
10 years and 15% of those followed up for 15 years
continued to have relapses.
The age at onset of disease was one of the many studied
prognostic factors. Trompeter et al (13) reported a longer
duration of illness observed in their patients, who
presented at an early age. Lewis et al (14) reported his
63 patients who had been followed up for 10 to 21 years.
Male sex and onset of disease under 5 years old were
independently associated with a higher rate of relapse.
Kabuki et al (6) also reported that in their 60 SSNS,
patients presented at an age of less than 4 years were
associated with greater likelihood of frequent relapses
and a longer time interval to attain remission. However,
the relationship between the frequency of relapses,
duration of disease and age of onset of symptoms was
not observed in our patients.
Nevertheless, a fewer number of relapses per year were
observed in the long-term remission group than that in
the active disease group, particularly from the second
year of follow-up onwards. The fewer the number of
relapses per year, the more likely they would go into
long-term remission. This coincided with the previous
observations, which reported a decline in frequency of
relapse with the duration of follow-up (14). The number
of relapses during the first 6 months of disease was
another set forth predictor. During the initial 6-month
period, the absence of a relapse predicted a favorable
outcome especially in the first 2 years and contrarily,
the occurrence of three or more relapses predicted a
frequent relapsing course (15). However, we could not
reproduce similar results. There was no statistically
significant difference in the outcome between patients
who relapsed within the first 6 months of disease and
patients who relapsed later. The outcome of those
frequent relapsers and infrequent relapsers, classified in
their first year of disease also did not show significant
difference.
Unremitting proteinuria during the initial 8 weeks of
treatment was unfavorable and its progression to end-
stage renal disease had been reported (17). These patients
were at risk for poor outcome and early use of cytotoxic
drugs should be contemplated before any irreversible
renal damage occurred. In our group, there was only one
patient who showed partial response to steroid and he
achieved remission after a course of cyclophosphamide.
Many clinical and laboratory characteristics observable
at the time of diagnosis had been studied in previous
reports. Majority of them did not show any relationships
between the numbers of relapses in the first 6 months
following response (15). Without great surprise, we did
not find any difference in most of the clinical and
laboratory parameters studied between relapsers and
nonrelapsers and between patients who went into long-
term remission and those with active disease. However,
we did notice that the nonrelapsers had a higher serum
albumin level than the relapsers at presentation. The
laboratory results were the first set of data that was
obtained when the patients were admitted to hospital.
Should the higher serum albumin reflect a milder disease
in this group of patients, or should it simply reflect the
timing when the child was brought to medical attention?
Hiraoka et al (16) studied their 66 SSNS and suggested
that patients without edema had a milder disease and
exhibited an extremely propitious clinical course. These
asymptomatic children were identified by chance
proteinuria on a urinary screening program. However,
these patients probably represented a different group of
patients in whom nephrotic syndrome may resolve
spontaneously without treatment. Furthermore, a group
of seven nonrelapsers was definitely too small to
substantiate the significance of a higher serum albumin
and to draw any persuasive conclusion from it. The small
number of nonrelapser was probably related to selection
bias since they were usually managed in private sectors
and were seldom referred for management.
There are many factors that determine the outcome and
influence the clinical course of idiopathic nephrotic
syndrome in childhood. These include the underlying
kidney pathology, the response to steroid and the use of
steroid sparing agents, particularly cytotoxic drugs and
cyclosporin A. Retrospective analysis of prognostic
factors is particularly difficult. Our patients were
categorized according to the number of relapses in each
year of follow-up and there were limitations to this
categorization. Firstly, our patients were instructed to
perform daily urine dipstick at home and relapses were
detected at an early stage if they complied in home
monitoring. A proportion of patients who relapsed
underwent spontaneous remission without treatment.
Those who did not have home monitoring may
underestimate the number of relapses. Was there any
difference between clinical relapse and biochemical
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relapse? Secondly, relapse may occur after long
remission and if the period of follow-up was not long
enough, we may overestimate the number of
nonrelapsers. Thirdly, our patients were enrolled at
different time and they had different duration of follow-
up. Fourthly, renal biopsies were not performed in all of
our patients.
Among the kidney biopsies performed, 71% showed
minimal change disease which was characterized by little
or no abnormality on light microscopy; mild or focal
mesangial hypercellularity was seen in some cases and
immunofluorescence study was negative or occasionally
weakly positive for IgM. Some of our patients were
classified as IgM nephropathy However, the existence
of IgM nephropathy as a distinct entity was still
contentious. Some studies had demonstrated increased
steroid resistance in IgM nephropathy and long-term
outcome is less affirmative when compared with minimal
change disease (18,19). However, recent data supported
that patients with the two histological diagnoses were
indistinguishable clinically (20).
We have tried to identify prognostic factors in predicting
the outcome of our patients whom we have categorized
into groups. However, it is a retrospective cohort of
patients and only 42 patients could be analyzed whereas
the records of many potential candidates were not
available. It was a common problem to retrospective
review, particularly when computerized record system
was lacking. Selection bias was an important drawback
in our review.
CONCLUSION
The long-term outcome of SSNS is favorable. None of
our patients had impaired renal function after being
followed up for a mean period of 10 ±3 years.
Nevertheless, a small percentage of them continued to
have active disease and relapses in their adult lives. The
fewer number of relapses per year, the more likely they
would go into long-term remission. It was observed that
a higher serum albumin at presentation may be associated
with a less relapsing course. Nevertheless, further studies
are required to verify its significance.
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